Accepted for Publication: December 5, 2014.
Published Online: March 30, 2015. doi:10.1001/jamaneurol.2014.4477.
Study concept and design: Nation, Edmonds, Bangen, Delano-Wood, Scanlon, Edland, Salmon, Galasko, Bondi.
Acquisition, analysis, or interpretation of data: Nation, Bangen, Delano-Wood, Scanlon, Han, Salmon, Bondi.
Drafting of the manuscript: Nation, Bangen, Bondi.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Nation.
Administrative, technical, or material support: Nation, Bangen, Delano-Wood, Scanlon, Han, Salmon, Bondi.
Study supervision: Bondi.
Conflict of Interest Disclosures: The Alzheimer’s Disease Neuroimaging Initiative is funded through generous contributions from the following: Araclon Biotech; BioClinica Inc; Biogen Idec Inc; Bristol-Myers Squibb; Eisai Inc; Elan Pharmaceuticals Inc; Eli Lilly and Co; EUROIMMUN; Hoffmann-La Roche Ltd and its affiliated company Genentech Inc; Fujirebio Diagnostics Inc; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research and Development LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace Inc; Merck Inc; Meso Scale Diagnostics LLC; NeuroRx Research; Neurotrack; Novartis Pharmaceuticals Corp; Pfizer Inc; Piramal Imaging; Laboratoires Servier; Synarc Inc; and Takeda Pharmaceutical Company.
Funding/Support: The current study was supported by grants R01 AG012674, K24 AG026431, P50 AG05131, and K23AG040625 from the National Institutes of Health, grant 1 IK2 RX001240 from the Department of Veterans Affairs, the National Institute on Aging, and the National Institute of Biomedical Imaging and Bioengineering. Data collection and sharing for this project were funded by grant U01 AG024904 from the National Institutes of Health (the Alzheimer’s Disease Neuroimaging Initiative) and grant W81XWH-12-2-0012 from the Department of Defense Alzheimer’s Disease Neuroimaging Initiative. The Alzheimer’s Disease Neuroimaging Initiative is funded through generous contributions from the Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation. The Canadian Institutes of Health Research provides funds to support the Alzheimer’s Disease Neuroimaging Initiative clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative database (http://adni.loni.usc.edu). As such, the investigators in the Alzheimer’s Disease Neuroimaging Initiative contributed to the design and implementation of the Alzheimer’s Disease Neuroimaging Initiative and/or provided data but did not participate in analysis or writing of this article. A complete listing of Alzheimer’s Disease Neuroimaging Initiative investigators is in eAppendix 1 in the Supplement.
Additional Information: Alzheimer’s Disease Neuroimaging Initiative data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The study was coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego.